RCD – Rousaud Costas Duran has advised AlbaJuna Therapeutics, a spin-off from the IrsiCaixa AIDS Research Institute, on the investment of €3.75M by the pharmaceutical company Grifols, which will support the development of therapeutic antibodies to fight HIV. The amount invested is expected to increase as each molecule development stage is completed.
Aelix Therapeutics is a spin-off of HIVACAT, a joint public and private sector consortium, internationally recognized in the fight against AIDS, which is composed of medical institutions and leading AIDS research centres such as the Institute for AIDS Research IrsiCaixa, University Hospital Germans Trias i Pujol and the AIDS and Infectious Diseases Service at Barcelona’s Hospital Clinic. HIVACAT conducts research into the development of a new HIV vaccine, in conjunction with the pharmaceutical company ESTEVE, and with the support of the “la Caixa” Foundation, the autonomous Catalan government’s Department of Economy and Knowledge plus the Clinic Foundation at Barcelona’s Hospital Clinic (ICREA) and the Gloria Soler Foundation. This consortium is the first major collaboration attempt between a local government, research centres and private enterprise in this field.
RCD’s Innovation team has led the legal advice on this transaction, considered a milestone in the public-private partnership in the field of biotechnology as RCD’s partner, Oscar Alegre, explains: “the funding round has resulted in the convergence of the interests of public research, pharmaceutical companies and specialized investors in the sector, both locally and internationally. The agreement was a challenge and the goodwill of all parties made it possible; it will certainly be a model for new projects in the future.”
RCD has wide experience advising public research institutions as well as biotech companies on technology transfer, public-private collaborative agreements, venture capital, regulatory issues, etc.
cloud technology axon
La necesidad de comprender los entresijos de los mercados internaciona...
